NYSE American - Nasdaq Real Time Price USD

China Pharma Holdings, Inc. (CPHI)

2.3100
+0.2100
+(10.00%)
As of 11:12:21 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Zhilin Li President, CEO, Chairman & Interim CFO 316k -- 1953
Ms. Huang Na C.F.A. BOD Secretary & IR Manager -- -- --

China Pharma Holdings, Inc.

No. 17, Jinpan Road
Second Floor
Haikou, 570216
China
86 89 8668 11730 https://www.chinapharmaholdings.com
Sector: 
Healthcare
Full Time Employees: 
224

Description

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Corporate Governance

China Pharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

April 4, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 31, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

December 26, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

November 12, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

November 1, 2024 at 12:00 AM UTC

PRE 14A: Proxy Statements

August 14, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 15, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 8, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers